Insilico Medicine
Data as of .
Company facts
-
Founded
2014
-
Headquarters
Hong Kong (Hong Kong Science Park); US office Cambridge, MA
Latest funding round
- Round
- IPO (HKEX)
- Date
- Dec 30, 2025
- Amount
- $293M
Drug discovery partners
6 pharma, 2 other. Pharma here means a company with approved products and roughly $1B or more in annual revenue.
-
Takeda Pharma
Discovery collaboration,
$60M upfront ($600M total potential)
-
Eli Lilly Pharma
License and research collaboration,
$115M upfront ($2.75B total potential)
-
Qilu Pharmaceutical Pharma
Co-development,
$120M total potential (upfront not disclosed)
-
Servier Pharma
Research collaboration,
$32M upfront ($888M total potential)
Show all (8)
-
Eli Lilly Pharma
Research and license,
$100M total potential (upfront not disclosed)
-
Menarini (Stemline) Pharma
Asset license,
$20M upfront ($550M total potential)
-
SK Biopharmaceuticals Biotech
Discovery collaboration,
$2.5B total potential (upfront not disclosed)
-
Hygtia Therapeutics Biotech
Co-development and license (ISM8969),
Terms not disclosed
Drugs on the board
- ISM8969 (NLRP3 inhibitor)
Phase 1 registry
Chronic neuroinflammation, including Parkinson's disease (company goal); the Phase 1 trial enrolls healthy adults and obese adults at cardiovascular risk
- Rentosertib
Phase 3 registry
Idiopathic pulmonary fibrosis
- ISM9546 (VAV1 molecular glue degrader)
Preclinical candidate per company
Autoimmune diseases including rheumatoid arthritis and IBD
- Rentosertib inhaled formulation
IND in effect (China CDE) per company
Idiopathic pulmonary fibrosis
Show all (11)
- ISM6331
Phase 1/2 registry
Mesothelioma and solid tumors
- ISM3412
Phase 1/2 registry
Locally advanced or metastatic solid tumors (MTAP-deleted)
- MEN2501
Phase 1 registry
Platinum-resistant ovarian cancer
- ISM1354 (GIPR antagonist)
Preclinical candidate per company
Obesity
- ISM9077 (Target Y inhibitor)
Preclinical candidate per company
Ocular, inflammatory and aging-related diseases
- Garutadustat (ISM5411, PHD inhibitor)
Phase 2 registry
Ulcerative colitis
- ISM8207 (QPCTL inhibitor)
Phase 1 registry
Advanced solid tumors and relapsed or refractory B-cell lymphoma
Recent news
-
Released MMAI KINOME kinase activity model, free to try
-
Released 4 free drug discovery models (ADMET, kinase selectivity, GPCR, synthetic chemistry)
-
Nominated ISM1354, AI-driven GIPR antagonist, as preclinical candidate for obesity
-
UAE team AI-designed BTK-targeting PROTACs for blood cancers
-
Nominated ISM9077 (Target Y inhibitor) as preclinical candidate for ocular and inflammatory diseases
Confirmed means the company, a partner or a filing said it. Reported means a third party said it. This section sits outside the Pharma AI Tracker.
Spot an error? Tell me and I'll fix it.